DICE Therapeutics
Mittie Doyle is a proven research physician who has held numerous leadership roles in clinical development. She has more than 20 years of experience in the pharmaceutical and biotech industries and academia. Prior to Aro Biotherapeutics, Mittie was vice president, global therapeutic area head, research & development, immunology at CSL Behring. Prior to her time at CSL, she held senior level roles at Shire Pharmaceuticals, Flexion Therapeutics and Alexion Pharmaceuticals.
During her career, Mittie has led clinical development across a broad range of immune mediated and orphan diseases. She has led teams with responsibilities for design and execution of first-in-human through Phase 2 and 3 trials, resulting in several global regulatory approvals.
Mittie holds a B.A. in romance languages from Princeton University and an M.D. from Yale Medical School. She completed her postdoctoral training at Harvard Medical School, including residency in internal medicine ,at Massachusetts General Hospital and clinical/research fellowship in rheumatology and immunology at Brigham and Women’s Hospital.
This person is not in the org chart
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.